Intrinsic Value of S&P & Nasdaq Contact Us

Mesoblast Limited MESO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • AU • USD

SharesGrow Score
39/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.50
-21.3%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Mesoblast Limited (MESO) has a negative trailing P/E of -23.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 157.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.29%, forward earnings yield 0.64%. PEG 0.69 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (63/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.69).
  • Forward P/E 157.3 — analysts expect a return to profitability with estimated EPS of $0.09 for FY2027.
  • PEG Ratio 0.69 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -4.29% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.64% as earnings recover.
  • Analyst consensus target $11.50 (-21.3% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 39/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score
39/100
SG Score
View full scorecard →
VALUE
63/100
Price-to-Earnings & upside
Proven by this page
FUTURE
16/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
62/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — MESO

Valuation Multiples
P/E (TTM)-23.3
Forward P/E157.3
PEG Ratio0.69
Forward PEG0.69
P/B Ratio3.17
P/S Ratio118.11
EV/EBITDA-38.0
Per Share Data
EPS (TTM)$-0.06
Forward EPS (Est.)$0.09
Book Value / Share$0.45
Revenue / Share$0.01
FCF / Share$-0.05
Yields & Fair Value
Earnings Yield-4.29%
Forward Earnings Yield0.64%
Dividend Yield0.00%
Analyst Target$11.50 (-21.3%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -103.2 1.07 0.81 10.01 -
2017 -11.1 -0.01 1.65 354.43 -
2018 -14.5 0.32 0.94 29.53 -
2019 -5.6 -0.04 1.04 29.86 -
2020 -15.5 0.93 2.19 37.46 -
2021 -9.2 -1.37 1.56 121.40 -
2022 -3.3 0.18 0.61 29.69 -
2023 -8.0 0.32 1.31 87.34 -
2024 -7.6 0.86 1.39 113.35 -
2025 -12.9 2.44 2.20 76.48 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-0.11 $42.55M $-4.13M -9.7%
2017 $-1.90 $2.41M $-76.82M -3184.7%
2018 $-0.76 $17.34M $-35.29M -203.5%
2019 $-1.80 $16.72M $-89.8M -537%
2020 $-1.50 $32.16M $-77.94M -242.4%
2021 $-1.60 $7.46M $-98.81M -1325.3%
2022 $-1.30 $10.21M $-91.35M -894.6%
2023 $-0.98 $7.5M $-81.89M -1091.7%
2024 $-0.89 $5.9M $-87.96M -1490.3%
2025 $-0.84 $17.2M $-102.14M -593.9%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.30 $-0.50 – $-0.10 $127.6M $111.26M – $154.3M 2
2027 $0.19 $0.15 – $0.24 $232.19M $202.46M – $280.77M 1
2028 $0.90 $0.75 – $1.14 $471.43M $411.07M – $570.06M 1
2029 $1.47 $1.23 – $1.87 $909.47M $793.02M – $1.1B 1
2030 $3.32 $2.77 – $4.22 $886.44M $772.93M – $1.07B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message